WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Filters
List of articles in category Pfizer
Title Published Date
Pfizer receives Breakthrough Therapy designation from FDA for PF-04965842, an oral JAK1 Inhibitor, for the treatment of patients with moderate-to-severe atopic dermatitis 14 February 2018
Pfizer announces positive top-line results for potential biosimilar to Rituxan® / MabThera® 25 January 2018
FDA approves new Pfizer biosimilar 15 December 2017
Pfizer enters into agreement to develop and commercialize CRESEMBA® (isavuconazole) in China and Asia Pacific region 01 December 2017
Pfizer receives FDA approval for SUTENT® (sunitinib malate) as first and only adjuvant treatment for adult patients at high risk of recurrent renal cell carcinoma 16 November 2017
Spark Therapeutics and Pfizer amend license agreement for investigational SPK-9001 in hemophilia B 08 November 2017
The Union for International Cancer Control and Pfizer award new round of grants totalling US$500,000 to organisations in 19 countries 23 October 2017
Pfizer reviewing strategic alternatives for Consumer Healthcare business 12 October 2017
Pfizer launches novel programs to put important support services at the fingertips of cancer patients 05 October 2017
Pfizer goes to Court to allow competition for biologics and expand options for patients 20 September 2017
Alliance Foundation Trials opens global trial investigating first-in-class palbociclib in HR+, HER2+ metastatic breast cancer 23 August 2017
FDA Advisory Committee votes in favor of XELJANZ® (tofacitinib citrate) for the treatment of active psoriatic arthritis 04 August 2017
Pfizer announces positive top-line results from the comparative REFLECTIONS B7391003 study for PF-06439535, a potential biosimilar to Avastin® (bevacizumab) 25 July 2017
Merck and Pfizer collaborate with Corning 20 July 2017
FDA Advisory Committee votes in favor of Pfizer's MYLOTARG (gemtuzumab ozogamicin) for acute myeloid leukemia 13 July 2017
BESPONSA® approved in the EU for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia 07 July 2017
Pfizer breaks ground on new R&D facility in Chesterfield, Missouri 28 June 2017
Pfizer and Lilly receive FDA Fast Track designation for tanezumab 13 June 2017
Pfizer receives FDA Fast Track designation for tafamidis for transthyretin cardiomyopathy 06 June 2017
FDA Advisory Committee recommends approval of Pfizer's proposed biosimilar to Epogen® / Procrit® across all indications 25 May 2017
  • Start
  • Prev
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • Next
  • End

Business & Industry

  • Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
  • CPHI Pharma Awards open to global innovators, scientists, entrepreneurs and social leaders
  • Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
  • BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
  • Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma

Research & Development

  • Candidate found to inhibit malignant melanoma growth
  • A nasal spray protects against coronavirus infection - Effective also against recent immune-evasive variants
  • 'Biohybrid' device could restore function in paralysed limbs
  • Scientists use tardigrade proteins for human health breakthrough
  • DNA treatment could delay paralysis that strikes nearly all patients with ALS
  • Scientists reveal a potential new approach to treating liver cancer
  • Normalizing tumor blood vessels may improve immunotherapy against brain cancer

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA approves first over-the-counter naloxone nasal spray
  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  1. You are here:  
  2. Home
  3. Pfizer
  4. Pfizer invests $43 billion to battle cancer

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.